Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Researchers develop new guidelines to treat recently diagnosed multiple myeloma patients

Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy.

2 Apr 2013

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced the results of a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia. Cancer cachexia is the complex, multi-symptom syndrome seen in late-stage cancer patients, characterized by anorexia and unintended loss of appetite, progressive and continual weight loss, accompanied by generalized host tissue wasting, skeletal muscle atrophy, immune and metabolic dysfunction, and a greatly diminished quality of life.

21 Mar 2013

TGen to present latest research about multiple myeloma at free public conference

The Translational Genomics Research Institute will present its latest research about a cancer known as multiple myeloma at a free public conference hosted by the Arizona Myeloma Network.

15 Mar 2013

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Aeterna Zentaris Inc. today announced that an independent Data Safety Monitoring Board has recommended discontinuing the ongoing Phase 3 study comparing the efficacy and safety of perifosine to placebo when combined with bortezomib (Velcade) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma.

12 Mar 2013

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).

4 Mar 2013

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

Bone marrow transplant is a key treatment for patients with leukemia, lymphoma, multiple myeloma and other blood disorders. University of Michigan researchers have discovered that inhibiting a signaling pathway in some of the transplanted cells could prevent the most serious potential complications of the procedure, a conflict between the transplanted cells and the recipient's own tissue called graft-versus-host disease.

2 Mar 2013

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Baylor Research Institute (BRI), the research arm of Baylor Health Care System, and TikoMed AB announced today that an agreement has been established to investigate TikoMed´s product IBsolvMIR® in a phase II clinical trial.

28 Feb 2013

Distinct bone marrow niches can nurture different types of blood stem cells

In research that could one day improve the success of stem cell transplants and chemotherapy, scientists have found that distinct niches exist in bone marrow to nurture different types of blood stem cells.

25 Feb 2013

Marine-based active substances show promise against multiple myeloma

There is fierce competition in the ocean habitat. In order to survive there, marine organisms defend themselves against their rivals using an entire arsenal of chemical weapons. With the help of these substances they attack hostile cells, overcome their defence system and thus are interesting active substance candidates for cancer research.

22 Feb 2013

TIR-199 shows promise in fighting renal cancer

Chemists at the University of California, Riverside have developed a compound that holds much promise in the laboratory in fighting renal (kidney) cancer.

20 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

MMRF joins multiple myeloma community in celebrating FDA accelerated approval of Pomalyst

The Multiple Myeloma Research Foundation (MMRF) today joined the multiple myeloma community in celebrating the U.S. Food and Drug Administration's (FDA) decision to grant accelerated approval of Pomalyst (Celgene Corporation, pomalidomide) for the treatment of patients with relapsed and refractory multiple myeloma who no longer respond to currently available treatments.

10 Feb 2013

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).

7 Feb 2013

Mcl-1 gene essential for survival of antibody-producing cells

Scientists have identified the gene essential for survival of antibody-producing cells, a finding that could lead to better treatments for diseases where these cells are out of control, such as myeloma and chronic immune disorders.

3 Feb 2013

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoEthix, the Swiss-based specialist in oncology drug development, announces progress in its Phase I study of OTX015, a novel BET bromodomain inhibitor, with the first dosing of a patient.

31 Jan 2013

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

OncoPep, Inc. today announced that the Company has initiated a Phase 1/2a clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma, an asymptomatic precursor of multiple myeloma, which is an incurable cancer of the plasma cells.

30 Jan 2013

New study may help treat patients with multiple myeloma

A study led by Robert G. Hawley, Ph.D., professor and chair of the department of anatomy and regenerative biology at the George Washington University (GW) School of Medicine and Health Sciences (SMHS), may help predict which patients with multiple myeloma will respond better to certain treatments.

25 Jan 2013

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

BioInvent International announced today the first results from the BI-505 phase I study in patients with multiple myeloma.

24 Jan 2013

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

Researchers at Moffitt Cancer Center and colleagues have investigated the safety, efficacy and the maximum tolerated dose of pomalidomide for patients with multiple myeloma who have disease relapsed after treatments with other drugs, such as bortezomib and lenalidomide.

24 Jan 2013

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

Researchers develop new guidelines to treat recently diagnosed multiple myeloma patients

Phase II trial results of OHR/AVR118 in patients with cancer cachexia announced

TGen to present latest research about multiple myeloma at free public conference

DSMB recommends discontinuation of Aeterna Zentaris’ perifosine Phase 3 study for MM

Chroma Therapeutics, CTI announce results from tosedostat Phase 2 study on AML

Global inhibition of all Notch signals would not be safe after bone marrow transplantation

TikoMed, BRI partner to investigate IBsolvMIR in phase II trial for chronic pancreatitis

Distinct bone marrow niches can nurture different types of blood stem cells

Marine-based active substances show promise against multiple myeloma

TIR-199 shows promise in fighting renal cancer

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

MMRF joins multiple myeloma community in celebrating FDA accelerated approval of Pomalyst

Novel combination of ibrutinib and bortezomib could be effective new therapy for blood cancers

Mcl-1 gene essential for survival of antibody-producing cells

OncoEthix initiates OTX015 Phase I study in hematologic malignancies

OncoPep commences PVX-410 Phase 1/2a trial in smoldering multiple myeloma

New study may help treat patients with multiple myeloma

Positive results from BioInvent's BI-505 phase I study on multiple myeloma

Pomalidomide safe, effective and extends overall survival for patients with multiple myeloma

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Multiple Myeloma News and Research

Latest Multiple Myeloma News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in